Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Shares of Oncolytics Biotech Inc. (TSE:ONC) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of C$14.82 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Price Performance

The stock has a 50-day moving average price of C$14.90 and a 200 day moving average price of C$14.82. The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Insider Activity

In other news, insider Jared Ryan Kelly acquired 29,500 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the acquisition, the insider owned 109,000 shares of the company’s stock, valued at C$126,440. The trade was a 37.11% increase in their ownership of the stock. Also, Director Wayne Pisano bought 30,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average price of C$1.16 per share, for a total transaction of C$34,800.00. Following the completion of the transaction, the director owned 288,306 shares of the company’s stock, valued at approximately C$334,434.96. The trade was a 11.61% increase in their position. Insiders have bought a total of 289,232 shares of company stock worth $335,760 over the last ninety days. 3.82% of the stock is owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.